

Intrathecal Administration of Melatonin via Implanted Pump for the Management of Neurodegenerative Disorders, Including Alzheimer's Disease: A Mechanical Pineal Gland Approach.

Qestor Z Nomycz

*Corresponding author

Qestor Z Nomycz,
Department of Neurological Surgery, Allegheny General
Hospital, Pittsburgh, USA.

Received Date : June 08, 2024

Accepted Date : June 10, 2024

Published Date : July 10, 2024

ABSTRACT

Numerous studies have demonstrated that severe oxidative and free radical damage to the brain is a common feature of human neurodegenerative illnesses, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and cerebellar ataxias. Actually, a wealth of data points to oxidative stress as the primary cause of neuronal cell loss and apoptosis in these types of illnesses. The brain possesses an intricate antioxidant system that has developed over time to continuously eliminate harmful free radicals and reactive oxygen species. It has long been hypothesized that a significant portion of the cognitive deterioration that comes with aging is connected to progressive oxidative damage to neurons. Nevertheless, regardless of the origin of these diseases, treatment approaches for their shared pathologic outcome, as a redox issue in the brain have been deficient. Oral or parenteral delivery of antioxidants has been the mainstay of antioxidant therapeutic options in human neurodegenerative illnesses; however, these approaches are likely limited in their ability to appreciably "reduce" the central nervous system due to the blood-brain barrier. In this article, I examine the data in favor of investigating intrathecal melatonin for neuroprotection and disease modification in neurodegenerative illnesses like Alzheimer's disease.

INTRODUCTION

While the exact etiology of neurodegenerative diseases like Alzheimer's disease is still unknown, oxidative damage to neurons is a well-established common theme in their pathogenesis. In fact, there is so much evidence supporting the oxidative stress theory in neurodegenerative illnesses that a textbook on the subject was written and published in 1997, 20 years ago [1]. Nonetheless, the brain's oxidative imbalance has not received much attention in terms of therapeutic interventions. Oxidative stress is most likely to affect the brain. Due to its high energy requirement (1/5 of total oxygen consumption and 1/6 of cardiac output), the brain is especially vulnerable to damage from free radicals. high levels of polyunsaturated fatty acids and a lot of transition metals, such iron, which could function as a catalyst to produce reactive oxygen species (ROS) and free radicals [2-4]. ROS include superoxide radical (O_2^-), hydroxyl radical (OH), and hydrogen peroxide (H_2O_2). Some ROS are free radicals, which are defined as having one or more unpaired electrons, as indicated by the dot notation, while others are not. Reactive nitrogen species (RNS) like peroxynitrite ($ONOO^-$) can also cause oxidative stress since they can easily damage proteins, lipids, carbohydrates, and DNA [1]. About 98% of molecular oxygen is used by the mitochondria at the cytochrome c oxidase complex during physiological conditions, and ROS are mostly produced by mitochondria during normal cellular respiration.

Age-related cognitive loss has been hypothesized to be mostly caused by oxidative damage to the brain, which worsens with age [6, 7]. The oxidative damage theory more clearly explains why neurons die in neurodegenerative illnesses, despite the fact that aberrant protein accumulation has received a lot of attention in these conditions. Free radicals, reactive oxygen species, and other reactive oxygen species (RNS) can cause necrosis and apoptosis in neuronal cells by destroying proteins, nucleic acids, carbohydrates, and lipids within a cell. Specifically, it has been determined that oxidative damage is the cause of cell suicide or apoptosis, and that anti-oxidant

The Journal of Alzheimer's Disease

enzyme overexpression and the addition of antioxidants can prevent apoptosis in neuronal cell lines [8–10]. Neurons possess many defense mechanisms to fend off hazardous oxidative products resulting from regular metabolism under normal circumstances. These redundant defense mechanisms include of non-enzyme substances (coenzyme Q, glutathione, and melatonin) as well as enzymes (superoxide dismutase, catalase, glutathione peroxidase, and phospholipid hydroperoxide glutathione peroxidase).

Hypothesis

One of nature's most powerful antioxidants and free radical scavengers for the central nervous system, melatonin, can be administered intrathecally through a pump to treat a variety of neurodegenerative diseases, including Alzheimer's. The etiology of Parkinson's disease (PD) appears to be strongly associated with ROS-induced oxidative stress. Neuroinflammation, mitochondrial dysfunction, and dopamine metabolism have all been connected to ROS in Parkinson's disease [15]. Significantly lower levels of reduced glutathione, elevated superoxide dismutase enzyme (which suggests a compensatory response to elevated superoxide radicals), elevated products of free radical lipid damage, such as lipid hydro peroxides and malondialdehydes, and elevated levels of DNA oxidative damage products, such as 8-hydroxyguanosine, have been found in the substantia nigra, the primary region of selective dopaminergic cell loss in Parkinson's disease (PD) [1]. The herbicide rotenone, which causes oxidative stress and the death of dopaminergic neurons in the substantia nigra, can induce experimental Parkinson's disease in rats [16]. MPTP, This results in complex I inhibition in the mitochondrial electron transport chain, which in turn produces high amounts of reactive oxygen species (ROS) and causes Parkinsonism in humans and primates [17]. Furthermore, it has been observed that PD patients have a specific increase in free iron in the substantia nigra, which is thought to catalyze the Fenton reaction, which produces ROS [18, 19]. Since dopamine can auto-oxidize to produce dopamine quinones and free radicals, it may be regarded as an unstable chemical. Impaired dopamine metabolism may also contribute to ROS in Parkinson's disease. Last but not least, PD-related proteins like alpha-synuclein have a tendency to congregate when reactive oxygen species (ROS) are present, and they can also promote ROS generation via influencing mitochondrial activity.

Lastly, oxidative stress in the central nervous system has been strongly linked to a number of neurodegenerative disorders, including cerebellar ataxias, Huntington's disease, and amyotrophic lateral sclerosis, in addition to the most common neurodegenerative disorders that have been

covered thus far [22–24]. Thus, addressing oxidative stress has emerged as a viable treatment approach for a variety of neurodegenerative conditions.

Neurodegenerative Diseases and Melatonin

It has been shown that melatonin (5-acetyl-5-methoxytryptamine) is an ancient chemical that reduces the metabolic threshold for oxygen [26]. Melatonin lowers oxidative damage through a variety of pathways, and evidence suggests that it has been conserved during billions of years of evolution in all living forms, including microbes. Melatonin has several anti-oxidant properties, such as direct free radical scavenging, promoting antioxidative enzymes, raising mitochondrial oxidative phosphorylation efficiency, lowering free radical production, and enhancing the effectiveness of other antioxidants [27]. In 1993, melatonin's potential as an antioxidant was first identified [28]. It is primarily delivered to the brain by direct secretion into the cerebrospinal fluid of the brain ventricular system, namely the third ventricle. It is produced in the vertebrate pineal gland and retina.

CONCLUSION

The pathophysiology of neurodegenerative disorders like Parkinson's and Alzheimer's disease is similar in that they are caused by oxidative brain damage. The brain may be more susceptible to age-related cognitive loss and neurodegenerative processes as a result of the age-related decrease in cerebrospinal melatonin, a crucial antioxidant mechanism in the central nervous system. A straightforward and innovative approach to disease modification in neurodegenerative illnesses is to increase the CSF melatonin concentration in a nocturnal temporal manner using an implanted intrathecal pump and catheter system. This approach merits clinical investigation.

REFERENCES

1. Beal MF, Howell N, Wollner I-B (1997) Mitochondria and Free Radicals in Neurodegenerative Diseases. Wiley, New Jersey, USA.
2. Uranga RM, Salvador GA (2018) Unraveling the burden of iron in neurodegeneration: intersection with amyloid beta peptide pathology. *Oxidative Medicine and Cellular Longevity* 2018: 2850341.
3. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. *Neurobiol Aging* 23: 795-807.
4. Esposito E, Cuzzocrea S (2010) Antiinflammatory

The Journal of Alzheimer's Disease

- activity of melatonin in central nervous system. *Curr Neuropharmacol* 8: 228-242.
5. Chance B, Sies H, Boveris A (1979) Hydroperoxide metabolism in mammalian organs. *Physiol Rev* 59: 527-605.
 6. Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. *Am J Physiol Regul Integr Comp Physiol* 292: 18-36.
 7. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS (2014) Mitochondrial oxidative stress in aging and healthspan. *Longev Healthspan* 3: 6.
 8. Hockenbery DM, Oltavi ZN, Yin X, Millman CL, Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 75: 241-251.
 9. Greenlund LJ, Deckwerth TL, Johnson EM Jr. (1995) Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. *Neuron* 14: 303-315.
 10. Tomel LD, Cope FO (1994) Apoptosis II: The Molecular Basis of Apoptosis in Disease. *Trends in Biochemical Sciences* 19: 392-393.
 11. Antolin I, Rodriguez C, Sain RM, Mayo JC, Uría H, et al. (1996) Neurohormone melatonin prevents damage: effect on gene expression for antioxidative enzymes. *FASEB J* 10: 882-890.
 12. Chung SY, Han SH (2000) Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. *J Pineal Res* 34: 95-102.
 13. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. *Biochim Biophys Acta* 1502: 139-144.
 14. Huang WJ, Zhang X, Chen WW (2016) Role of oxidative stress in Alzheimer's disease. *Biomed Rep* 4: 519-522.
 15. Hwang O (2013) Role of oxidative stress in Parkinson's disease. *Exp Neurobiol* 22: 11-17.
 16. Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. *Brain Res Mol Brain Res* 134: 109-118.
 17. Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson's disease. *Front Neuroanat* 9: 91.
 18. Sziraki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ, et al. (1998) Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in iron-induced animal model of parkinsonism. *Neuroscience* 85: 1101-1111.
 19. Youdim MB, Ben-Shachar D, Riederer P (1991) Iron in brain function and dysfunction with emphasis on Parkinson's disease. *Eur Neurol* 31: 34-40.
 20. Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson's disease. *J Parkinsons Dis* 3: 461-491.
 21. Surguchov A (2015) Intracellular dynamics of synucleins: "Here, There and Everywhere". *Int Rev Cell Mol Biol* 320: 103-169.
 22. Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. *Biochim Biophys Acta* 1762: 1051-1067.
 23. Gil-Mohapel J, Brocardo PS, Christie BR (2014) The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates? *Curr Drug Targets* 15: 454-468.
 24. Guevara-Garcia M, Gil-del-Valle L, Velasquez-Perez L, Garcia-Rodriguez JC (2012) Oxidative stress as a cofactor in spinocerebellar ataxia type 2. *Redox Rep* 17: 84-89.
 25. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanism to clinical applications. *Oxidative Medicine and Cellular Longevity* 2017: 2525967.
 26. Manchester LC, Coto-Montes A, Boga JA, Andersen LPH, Zhou Z, et al. (2015) Melatonin: an ancient molecule that makes oxygen metabolically tolerable. *J Pineal Res* 59: 403-419.
 27. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, et al. (2003) Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. *Acta*

Biochim Pol 50: 1129-1246.

28. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ, et al. (1993) Melatonin: A potent, endogenous hydroxyl radical scavenger. *Endocrine* 1: 57-60.
29. Reiter RJ, Tan DX, Kim SJ, Cruz MH (2014) Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. *Brain Struct Funct* 219: 1873-1887.
30. Tan D-X, Manchester LC, Sanchez-Barcelo E, Mediavilla MD, Reiter RJ (2010) Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system. *Curr Neuropharmacol* 8: 162-167.
31. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF (1999) Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. *J Clin Endocrinol Metab* 84: 323-327.
32. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pevet P, et al. (1990) Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. *Brain Res* 528: 170-174.
33. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF (2003) Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. *J Pineal Res* 35: 125-130.
34. Cardinali DP, Furio AM, Brusco LI (2010) Clinical aspects of melatonin intervention in Alzheimer's disease progression. *Curr Neuropharmacol* 8: 218-227.
35. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R (2006) Melatonin in Alzheimer's disease and other neurodegenerative disorders. *Behav Brain Funct* 2: 15.
36. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. (2000) The absolute bioavailability of oral melatonin. *J Clin Pharmacol* 40: 781-784.
37. Di WL, Kadva A, Johnston A, Silman R (1997) Variable bioavailability of oral melatonin. *New Eng J Med* 336: 1028-1029.